SIL index, comprising stage, soluble interleukin‐2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B‐cell lymphoma

Rituximab (R) plus doxorubicin, cyclophosphamide, vincristine, and prednisolone (CHOP) chemotherapy (R‐CHOP) is widely accepted as standard care for diffuse large B‐cell lymphoma (DLBCL) patients. The revised International Prognostic Index (R‐IPI) was established in 2007 after the addition of rituxi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Sci
Huvudupphovsmän: Tomita, Naoto, Sakai, Rika, Fujisawa, Shin, Fujimaki, Katsumichi, Taguchi, Jun, Hashimoto, Chizuko, Ogawa, Koji, Yamazaki, Etsuko, Ishigatsubo, Yoshiaki
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2012
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7659199/
https://ncbi.nlm.nih.gov/pubmed/22587388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02331.x
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk